2021 Deal Action In India: Watch Private Equity And E-Pharmacy
Pharma Deal Making Vibrant After 2020 COVID-19 Deals
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
You may also be interested in...
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Reliance Life Sciences, part of India’s largest private sector enterprise with a growing engagement in healthcare, is progressing an early-stage COVID-19 vaccine. A top executive underscores the potential to manufacture at scale and provide the protein-based candidate at a competitive price.